0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Lab Reports |

Anthrax and Cancer

Tracy Hampton, PhD
JAMA. 2008;299(5):513. doi:10.1001/jama.299.5.513-b.
Text Size: A A A
Published online

Extract

A modified anthrax toxin may be an effective cancer therapy, as indicated by studies led by investigators at the National Institutes of Health (Liu S et al. J Biol Chem. 2008;283[1]:529-540).

To give anthrax toxin high tumor specificity, the team developed anthrax toxin variants that require activation by matrix metalloproteinases, proteins that are overproduced in cancer cells.

When the investigators tested a mutated toxin in mice, 100% of the animals tolerated a dose that would otherwise have been lethal. The modified toxin was better at killing melanoma tumors than the natural toxin due to its higher specificity and longer half-life in the blood. The modified toxin also could kill other types of cancer cells, such as those from colon and lung tumors. The investigators found that this anticancer activity largely reflected the indirect targeting of tumor vasculature and angiogenic processes.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

New research suggests that a modified anthrax toxin has potential as an anticancer therapy.

(Photo credit: Scott Camazine/www.sciencesource.com)

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
[Histopathology of Orf]. Ann Dermatol Venereol 2013 Aug-Sep;140(8-9):571-3.
Jobs
brightcove.createExperiences();